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Objective: Ischemia/reperfusion injury caused by cardioplegic arrest is still a major challenge in patients with
reduced left ventricular function. We investigated the effect of chronic versus acute administration of the selective
endothelin-A receptor antagonist (ERA) TBC-3214Na during ischemia/reperfusion in failing hearts.
Methods: Male Sprague–Dawley rats underwent coronary ligation. Three days after myocardial infarction (MI),
19 randomly assigned animals (ERA chronic) were administered TBC-3214Na continuously with their drinking
water, 29 MI rats received placebo, and 3 rats died during the observation period. Six weeks after infarction, hearts
were evaluated in a blood-perfused working heart model during 60 minutes of ischemia and 30 minutes of reper-
fusion. In 14 MI rats, TBC-3214Na (ERA acute) was added to the cardioplegic solution during ischemia. Thirteen
MI rats served as control.
Results: At a similar infarct size, postischemic recovery of cardiac output (ERA chronic: 91%  10%, ERA
acute: 86%  11% vs control: 52%  15%; P< .05) and external heart work (ERA chronic: 90%  10%,
ERA acute: 85%  13% vs control: 51%  17%; P < .05) was significantly enhanced in both TBC-
3214Na–treated groups whereas recovery of coronary flow was only improved in ERA acute rats (ERA acute:
121% 23% vs ERA chronic: 75% 13%; control: 64% 15%; P<.05). Blood gas measurements showed
enhanced myocardial oxygen delivery and consumption with acute TBC-3214Na therapy. Additionally, high-
energy phosphates (phosphocreatine) were significantly higher and transmission electron microscopy revealed
less ultrastructural damage under acute TBC-3214Na administration.
Conclusion: Acute endothelin-A receptor blockade is superior to chronic blockade in attenuating ischemia/reper-
fusion injury in failing hearts. Therefore, acute endothelin-A receptor blockade might be an interesting option for
patients with heart failure undergoing cardiac surgery.
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Cardiac surgery is confronted with an increasing number of
patients with severe heart failure. Especially in patients with
reduced left ventricular (LV) function, poor postischemic
recovery owing to intraoperative ischemia/reperfusion (I/R)
injury is a major challenge to surgeons and anesthesiologists.
Currently used standard cardioplegic solutions provide
a high level of myocardial protection in elective cardiac op-
erations and in patients with an average risk profile. For
high-risk patients with severely reduced LV function, im-
From the Department of Cardiac Surgery, LK St Poeltena; the Ludwig Boltzmann
Cluster for Cardiovascular Researchb; the Institute of Physiological Chemistry,
Center of Physiological Medicine, Medical University Grazc; and the Departments
of Pathologyd and Pediatrics,e Vienna Medical University, Vienna, Austria.
Received for publication April 4, 2008; revisions received Oct 6, 2008; accepted for
publication Oct 27, 2008.
Address for reprints: Bruno K. Podesser, MD, Ludwig Boltzmann Cluster for Cardio-
vascular Research, C/O Core Unit for Biomedical Research, Medical University of
Vienna, Vienna General Hospital, Wa¨hringer Gu¨rtel 18-20, 1090 Vienna, Austria
(E-mail: bruno.podesser@meduniwien.ac.at).
J Thorac Cardiovasc Surg 2009;137:1005-11
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2008.10.037The Journal of Thoracic and Caprovements in cardioprotection seem to be more crucial. A
potential target for a further increase of cardioprotection
may lie in the endothelin system.1 On the one hand, endothe-
lin-1 (ET-1), the major isoform, is responsible for the pro-
gression and maintenance of cardiac remodeling after
myocardial infarction (MI), leading to the chronic process
of heart failure; on the other hand, ET-1 plays an important
role in acute I/R injury.2,3 The effects of ET-1 are mediated
by two receptor subtypes: ETA receptors induce vasocon-
striction and cellular proliferation and are mainly located
in the medial smooth muscle cell layers of blood vessels,
as well as the atrial and ventricular myocardium.4 ETB re-
ceptors are located on endothelial cells and to some extent
on vascular smooth muscle cells and macrophages. Activa-
tion of the ETB receptor leads to the release of nitric oxide
and prostacyclin and prevents apoptosis.5 Several experi-
mental studies revealed in both global6-9 and local10 I/R
a positive effect of selective ETA and combined ETA/ETB re-
ceptor blockade on hemodynamic performance, endothelial
function, MI size, inflammatory response, and oxidative
stress. All these results were obtained for healthy hearts
with normal cardiac function before I/R injury.
We tested two hypotheses: (1) Does acute administration
of the selective ETA receptor antagonist (ERA) TBC-
3214Na as adjunct to standard blood cardioplegic solution
improve postischemic recovery of cardiac function andrdiovascular Surgery c Volume 137, Number 4 1005




ADP ¼ adenosine diphosphate
AMP ¼ adenosine monophosphate
ATP ¼ adenosine triphosphate
CO ¼ cardiac output
ERA ¼ endothelin-A receptor antagonist
ET ¼ endothelin
I/R ¼ ischemia/reperfusion
LV ¼ left ventricle
MDO2 ¼ myocardial oxygen delivery
MI ¼ myocardial infarction
MVO2 ¼ myocardial oxygen consumption
PCr ¼ phosphocreatine
WH ¼ working heart mode
rWH ¼ working heart mode during reperfusion
metabolism in failing rat hearts. (2) Additionally, one group
of failing hearts, chronically treated with ERA, underwent
the same I/R protocol to test whether there is any positive




MI was induced in 48 male Sprague–Dawley rats by ligation of the left
anterior descending coronary artery as described previously.11 All animals
had free access to standard rat chow and water during the 6-week observa-
tion period and received humane care in compliance with the European
Convention on Animal Care. The experiments were approved by the Com-
mittee for Animal Research, Vienna Medical University.
Experimental Protocol and Perfusion System
Three days after MI, the surviving animals were randomized into two
groups. The first group (ERA chronic; n ¼ 19) of animals received the
ETA selective receptor blocker TBC-3214Na (45 mg/kg body weight),
whereas the second group (MI; n ¼ 29) received a placebo. Both TBC-
3214Na and placebo were added to the drinking water during the 6-week
observation period. In the observation period, 1 rat in the ERA chronic
group and 2 in the MI group died.
The 27 MI rats of the placebo group were randomly divided for the acute
experiments. Fourteen rats received TBC-3214Na as adjunct to cardioplegic
solution starting with the induction of cardiac arrest (ERA acute; n¼ 14). In
the other MI rats (control; n¼ 13), as well as in the ERA chronic group (n¼
18), standard cardioplegic solution was used without adjunct. Primarily, the
effect of TBC-3214Na on the change of coronary flow was assessed in the
Langendorff model. Starting with 10 mg/kg body weight, we enhanced the
dosage stepwise in 5-mg increments. At 30 mg/kg, a significant change in
coronary blood flow was detected as compared with baseline. This dose
was chosen for intracoronary application.
Six weeks after MI, in vivo hemodynamic measurements were per-
formed by transthoracic echocardiography. Then the rats were heparinized
with 200 IU/kg intravenously and the hemodynamic performance of the ex-
cised hearts was evaluated on an isolated red-cell perfused working heart
system (Hugo Sachs Elektronik, Freiburg, Germany), as described by Po-
desser and associates.12 The perfusion experiment was conducted according
to the standardized time schedule depicted in Figure 1. In the Langendorff
mode (LD before ischemia, rLD during reperfusion), the coronary arteries1006 The Journal of Thoracic and Cardiovascular Swere perfused at a constant pressure of 70 mm Hg. After cannulation of
the left atrium for conversion to the working heart mode (WH), the LV
was ejecting against a predefined afterload corresponding to a mean aortic
pressure of 70 mm Hg. For induction of cardioplegic arrest, cold blood car-
dioplegic solution according to Buckberg (Buckberg Kardioplegie; Ko¨hler
Chemie GmbH, Alsbach-Ha¨hnlein, Germany; 4:1 ratio of perfusate to
Buckberg’s stock solution, 4C at a mean aortic pressure of 50 mm Hg)
was used.
After evaluation on the isolated heart, 5 randomly picked animals per
group were taken to evaluate infarct size. In the other hearts, biochemical,
histologic, and ultrastructural analyses were performed.
Drugs
TBC-3214Na is both an orally active and parenterally applicable selec-
tive ETA receptor antagonist. It is a follow-on candidate of sitaxsentan
(TBC-11251) with a 25% higher oral bioavailability and a half-life of
more than 4 hours. The drug was kindly provided by Encysive Pharmaceu-
ticals, Houston, Texas.
In Vivo Hemodynamic Data Acquisition
Six weeks after MI, the animals were evaluated by transthoracic echocar-
diography as described previously.11 Imaging was done by an ultrasonogra-
pher experienced in rodent imaging and blinded to the study groups.
Ex Vivo Hemodynamic Data Acquisition
Hemodynamic data were obtained from the predefined time points: WH5
(baseline values), which indicates the time point measured in minutes after
conversion from Langendorff perfusion to the working heart mode before
ischemia, and rWH5, rWH10, rWH15, rWH25, rWH30, which stand for
the respective time points in the reperfusion period.
All hemodynamic values were registered as mean values derived from
the respective pressure and flow tracings. The following parameters were
assessed: cardiac output (CO, mL/min) identical to left atrial flow (Flowme-
ter Narcomatic RT-500, Narco Biosystems) in a closed circuit perfusion;
external heart work (g3 m/min, calculated as CO3 LV systolic pressure),
indicating pressure volume work performed per minute; and coronary flow
(mL/min). As mean aortic pressure remained constant during all phases of
perfusion, variations in coronary flow primarily reflect alterations in coro-
nary resistance, allowing assessment of function of microvasculature. LV
systolic pressure was measured by a high-fidelity MicroTip catheter (Millar
SP-407; Millar Instruments, Inc, Houston, Tex) introduced into the LV. Di-
astolic compliance was assessed by measurement of diastolic left atrial
pressure. Three hearts in the ERA chronic, 2 in the ERA acute, and 1 in
the control group did not reach sufficient CO at baseline WH5 (CO>15
mL $ min1 $ g1) and were excluded from further analysis. The hemody-
namic data of the reperfusion period are presented as recovery (mean per-
centage of baseline values) to adjust for differences in baseline between
groups.
FIGURE 1. Time schedule of the perfusion protocol. LD, Langendorff
mode; WH, Working heart mode; rLD, Langendorff mode during reperfu-
sion; rWH, Working heart mode during reperfusion. Cardioplegic arrest
was induced (I, induction) by cold blood cardioplegia according to Buck-
berg. Cardioplegia continued with two cold reinfusions (1. R, 2. R) and
was finished by a ‘‘hot shot.’’urgery c April 2009
Trescher et al Cardiopulmonary SupportTABLE 1. Echocardiographic, baseline working heart, and morphometric data
Control (n ¼ 12) ERA chronic (n ¼ 15) ERA acute (n ¼ 12)
Part 1: Echocardiographic data
LVEDD (cm) 1.14  0.05 1.01  0.01* 1.2  0.04
LVESD (cm) 1.01  0.06 0.82  0.01* 1.05  0.02
EF 0.28  0.04 0.44  0.01* 0.30  0.02
Part 2: Baseline working heart data
CF (mL $ min1 $ g1 HW) 2.72  0.35 2.71  0.48 2.89  0.51
CO (mL $ min1 $ g1 HW) 20.06  3.68 32.94  2.86* 22.98  4.62
EHW (g 3 m/min) 3365  427 5963  737* 3862  613
Part 3: Morphometric data Control (n ¼ 5) ERA chronic (n ¼ 5) ERA acute (n ¼ 5)
BDW (g) 446.6  27.4 440.1  38.1 439.6  24.9
Infarct size (%) 46.2  3.7 47.5  2.1 45.8  3.5
Total HW (g) 2.24  0.34 1.95  0.19 2.34  0.38
LV/BDW 3.28  0.11 2.68  0.18* 3.34  0.2
LVEDD, Left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; EF, ejection fraction; CF, coronary flow; HW, heart weight; CO, cardiac output;
EHW, external heart work (calculated as CO3 LV systolic pressure); BDW, body weight; LV, left ventricular. Data are presented as mean  SEM. *P< .05 vs both control and
ERA acute group.C
P
SMorphometric and Histologic Evaluation
To evaluate the extent of heart failure, in addition to echocardiography,
we determined infarct size and myocardial hypertrophy. Therefore, at the
end of the ex vivo experiment, 5 random hearts from each group underwent
morphometric examination.13 Infarct size was expressed as the ratio of the
infarct region to total LV mass.
All other hearts (ERA acute n ¼ 7, ERA chronic n ¼ 10, control n ¼ 7)
underwent two different protocols for tissue processing at the end of the iso-
lated heart perfusion. This enabled the evaluation of both biochemical and
histologic changes in one heart: Hearts were switched back to the Langen-
dorff mode again after the reperfusion period was finished. The first protocol
was used to obtain samples for the measurement of high-energy phosphates:
a freeze-clamped specimen of the noninfarcted septum close to the apex was
taken from the beating heart and immediately frozen in liquid nitrogen. The
second protocol was used to determine ultrastructural damage of myocardial
tissue by electron microscopy: after the septal biopsy, the heart was flushed
with Krebs–Henseleit buffer again to wash out erythrocytes. Then a small
tissue sample from the upper part of the septum was fixed in a 4% buffered
paraformaldehyde solution containing 0.1% glutaraldehyde for further his-
tologic examination. Electron microscopy was performed according to stan-
dard procedures described before.14
Biochemical Evaluation
Arterial and coronary sinus blood samples were collected at time point
WH5 before ischemia and rWH15 during reperfusion. Blood gas analysis
was performed and the following parameters were calculated: myocardial
oxygen consumption (MVO2), myocardial oxygen delivery (MDO2), and
cumulative lactate according to the formula described by Dworschak and
associates.15 The high-energy phosphates adenosine monophosphate
(AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP),
and phosphocreatine (PCr) were analyzed by high-performance liquid chro-
matography as described previously.16 Energy charge (EC) was calculated
according to the following formula: EC ¼ (ATPþ½ ADP)/(ATPþADPþ
AMP).
Statistical Analysis
All data are expressed as mean  SEM. Analysis of variance was per-
formed with GraphPad Prism Statistical Software 4.0 (GraphPad Software,
Inc, La Jolla, Calif). Whenever significance was indicated, Bonferroni mul-
tiple comparison analysis was performed to compare between groups.The Journal of Thoracic and CRESULTS
Animal Characteristics
The first part of Table 1 and Table E1 summarizes the
results of in vivo hemodynamic measurements. In transtho-
racic echocardiography, 42 days after MI the animals receiv-
ing TBC-3214Na chronically with their drinking water
showed less systolic and diastolic LV dilatation (P< .05)
than did the control and ERA acute groups. Consequently,
ejection fraction as a marker of LV function was higher in
the chronic treatment group (P< .05) than in the control
and ERA acute groups.
The second part of Table 1 shows baseline hemodynamic
findings on the working heart apparatus at time point 5 Min-
utes (WH5). Comparison of preischemic baseline values
recorded during WH5 confirmed the echocardiographic
evaluation indicating a superior LV function in the chronic
treatment group in comparison with the control and ERA
acute groups, whereas there was no difference between con-
trol and ERA acute groups at baseline. In coronary flow per
gram heart weight, there was no difference in preischemic
baseline values among all groups.
The third part of Table 1 summarizes the morphometric
characteristics of the 5 representative hearts per group. At a
comparable infarct size, the difference in LV to body weight
ratio reached statistical significance in the ERA chronic group
versus the control and ERA acute groups (P< .05), indicat-
ing reduced LV hypertrophy with chronic ERA treatment.
Ex Vivo Hemodynamic Data
Comparison of postischemic recovery of hemodynamic
function showed the following results (Figure 2 and
Figure E1): Recovery of coronary flow was significantly en-
hanced in the ERA acute group compared with both the ERA
chronic and control groups (P< .01; Figure 2, A). For leftardiovascular Surgery c Volume 137, Number 4 1007
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SFIGURE 2. Ex vivo hemodynamic measurements. Data of the reperfusion period are presented as recovery values (percentage of baseline). A, Recovery of
coronary flow (CF)ERA acute versus both ERA chronic and control groups, *P<.01 (BL, baseline). B, Recovery of cardiac output (LAF, left atrial flow) ERA
acute versus control group, *P<.01; ERA chronic versus control group, #P<.01. C, Recovery of external heart work (EHW) (cardiac output3 LV systolic
pressure). ERA acute versus control group, *P<.01; ERA chronic versus control group; #P<.01. D, Recovery of diastolic left atrial pressure (LAP), *P<.01
ERA acute versus control group. All data are presented as mean  SEM.atrial flow, which is identical to CO in a closed circuit perfu-
sion, both treatment groups showed improved recovery ver-
sus control (P< .01; Figure 2, B). For LV systolic pressure,
there was only a trend toward improved recovery in the ERA
acute group, which did not reach statistical significance (data
not shown). Recovery of external heart work again was sig-
nificantly higher in both the ERA acute and ERA chronic
groups compared with the control group (P<.01 vs control;
Figure 2, C). Postischemic left atrial pressure as an indicator
for LV compliance was significantly reduced in the ERA
acute group compared with the control group (P< .01),
whereas there was no significant difference between the
ERA chronic group and the control group (Figure 2, D).
Histologic Evaluation
Ultrastructural changes were evaluated in 5 specimens per
group in 3 randomly selected fields in a blindfold manner and
graded according to the criteria of Schaper and colleagues.17
In the control group, 4 of 5 specimens showed severe to irre-
versible ischemic injury. In 1 specimen damage was graded
as moderate to severe. In the chronic treatment group, 2 spec-
imens showed severe to irreversible injury, and 3 specimens
showed moderate to severe ischemic damage. In the acute
treatment group, none of the hearts showed severe to irre-
versible injury, 3 hearts showed moderate ischemic damage,
and 2 hearts showed slight to moderate damage. Representa-
tive micrographs are depicted in Figure 3.1008 The Journal of Thoracic and Cardiovascular SBiochemical Data
There were no significant differences in preischemic
MVO2 between the control group and the ERA acute
group. However, by comparison, MVO2 was significantly
lower in the ERA chronic group (Table 2). During reper-
fusion, MVO2 did not decrease significantly compared
with the preischemic values in all 3 groups. In the ERA
chronic group, MVO2 remained low during reperfusion
compared with the control and ERA acute groups, with
no significant difference between the control and ERA
acute group.
Before ischemia, MDO2 was comparable among the 3
groups. During reperfusion, there was no difference between
the control and ERA chronic groups, whereas in ERA acute
MDO2 was significantly increased, indicating improved cor-
onary perfusion (P< .01).
At baseline, cumulative lactate did not differ among all
groups; after ischemia, cumulative lactate was significantly
reduced in both the ERA acute and ERA chronic groups
compared with the control group.
Postischemic evaluation of high-energy phosphates re-
vealed the superior preservation of acutely ERA treated
hearts (Figure 4, A). Phosphocreatine, the buffering energy
source for ATP in situations of energy demand, was signif-
icantly higher only in the acutely ERA treated hearts com-
pared with the control hearts (P< .01), whereas ATP was
significantly elevated in both the acute and chronic treatmenturgery c April 2009
Trescher et al Cardiopulmonary SupportFIGURE 3. Representative micrographs of transmission electron microscopy at the end of reperfusion. A, Control. B, ERA chronic. C, ERA acute. In A and
B, swelling and disruption of mitochondrial cristae and myofilaments indicate severe ischemic injury. In C, the integrity of mitochondria and myofilaments are
preserved by TBC-3214 treatment during I/R.C
P
Sgroups compared with the control group (P< .05). Energy
charge was also significantly higher only in the ERA acute
group compared with the control group (0.82  0.01 vs
0.73  0.01; P< .01), whereas the ERA chronic group
(0.80  0.02) did not reach significance (Figure 4, B). The
ATP/ADP and PCr/ATP ratios showed a similar picture
(ATP/ADP: ERA acute group: 3.41  0.19 vs control:
1.50  0.27; P<.01; ERA chronic: 2.95  0.28 vs control;
P<.05; PCr/ATP: ERA acute: 2.23  0.10 vs control: 0.78
 0.21; P< .01; ERA chronic group: 1.72  0.35 control;
P ¼ not significant).
DISCUSSION
The aim of the present study was to evaluate the effect of
long-term versus acute administration of a selective ETA-re-
ceptor blocker in failing hearts under the conditions of I/R.
When comparing hemodynamic recovery between chronic
and acute administration of TBC-3214Na, there is an equal
protection with either strategy used with the exception of
coronary flow. However, energy metabolism and ultrastruc-
tural damage data reveal that only acute ETA-receptor block-
ade provides superior myocardial protection compared with
chronic blockade. These data suggest that improvement of
coronary blood flow is responsible for superior protection
by preventing vasoconstriction caused by endothelial dys-
function.
In healthy hearts, several studies using both ETA selective
and combined ETA/ETB receptor antagonists demonstrated
a protective role in I/R. In a model of local I/R, by ligation
and subsequent reperfusion of the left anterior descending
coronary artery, a reduction of infarct size and oxidative
damage10 could be achieved by ERA. In isolated heart prep-
arations similar to our model, different receptor antagonists
led to an improvement of systolic and diastolic cardiac func-
tion,6 coronary artery blood flow,7 endothelial function, and
to a reduction of the no-reflow area8 and ischemic contrac-
ture.9The Journal of Thoracic and CTo the best of our knowledge, for the first time in the pres-
ent study acute administration of a selective ETA receptor
antagonist showed similar results in failing rat hearts. Using
both selective ETA
18,19 and unselective ETA/ETB
20,21 recep-
tor blockers, we demonstrated a close relationship between
the endothelin system and nitric oxide, suggesting that the
protective effect of ERA was mediated by enhancing the
bioavailability of nitric oxide und consequently preserving
endothelial function.
Similar results can be achieved by the administration of
angiotensin-converting enzyme inhibitors during I/R in iso-
lated cardiomyocytes22 and as adjunct to cardioplegia in
both nonfailing14,23 and failing24 hearts in isolated organ
perfusion systems. These studies suggest a nitric oxide–in-
duced mechanism as well preventing endothelial dysfunc-
tion and thereby enhancing postischemic myocardial
function, metabolism, and ultrastructural integrity. In our
laboratory in a protocol24 similar to that used in the current
study, the administration of quinaprilat with Buckberg blood
cardioplegic solution in failing rat hearts improved postis-
chemic recovery of hemodynamic values and myocardial








Baseline 0.06  0.01 0.03  0.01* 0.06  0.00z
Reperfusion 0.05  0.00 0.03  0.00y 0.06  0.01z
MDO2
Baseline 0.37  0.03 0.39  0.05 0.46  0.03
Reperfusion 0.30  0.04 0.26  0.03 0.53  0.05*z
Lactate
Baseline 2.87  0.40 1.75  0.52 2.49  0.35
Reperfusion 5.63  0.98 2.32  0.51* 2.99  0.42y
MVO2, Myocardial oxygen consumption (mL $ min
1 $ g1 heart weight); MDO2,
myocardial oxygen delivery (mL $ min1 $ g1 heart weight). Data are presented as
mean  SEM. *P< .01 vs control; yP< .05 vs control; zP< .05 vs ERA chronic
group.ardiovascular Surgery c Volume 137, Number 4 1009
Cardiopulmonary Support Trescher et al
C
P
SFIGURE 4. High-energy phosphates in biopsy tissue of the LV in the treatment groups receiving ERA compared with the control group. Changes in phos-
phocreatine and adenine nucleotide levels (A) and energy charge (B) in ERA the chronic and acute groups versus the control group; *P<.01 versus control;
#P< .05 versus control. PCr, Phosphocreatine; AMP, adenosine monophosphate; ADM, adenosine diphosphate; ATP, adenosine triphosphate.energy metabolism. In the present study, long-term adminis-
tration of TBC-3214Na after MI led to an attenuation of
cardiac remodeling as indicated by reduced cardiac hyper-
trophy, reduced LV dilatation, and enhanced cardiac func-
tion indicated by baseline morphology and hemodynamic
performance.
Similar results have been obtained in several studies using
both selective and unselective ERA in animal models of
heart failure.25,26 The ETA blocker was started on day 3 after
MI because when started earlier negative effects on infarct
healing, scar formation, and LV remodeling have been re-
ported.27,28 A reduction of LV diameter diminishes wall ten-
sion according to the law of LaPlace. This is accompanied
by a reduction of LV mass and consecutively reduced oxy-
gen consumption. Thereby the positive influence on LV ge-
ometry and metabolism enhances myocardial tolerance to I/
R. This might serve as an explanation for the improvement
of postischemic recovery of cardiac function compared
with control despite no enhancement in coronary artery
blood flow when TBC-3214Na is administered chronically
and standard cardioplegic solution is used during I/R. An-
other possible mechanism for the difference between acute
and chronic treatment is the fact that during I/R there is
a massive increase in ET-1 levels arising from injured tissue.
Only in the acute treatment group is the ETA-blocker present
at relevant concentrations in the perfusion medium at the
time point and site of injury. Therefore, the superiority of
acute versus chronic administration of ERA in preserving
endothelial function renders the use of ERA as adjunct to
cardioplegia only during I/R. Further research, however, is
needed to get clear insight into the entire mechanism behind
the differences observed between acute and chronic admin-
istration and the potentially positive effect of ERA when
used in the setting of the cardiac operating room.
As a conclusion from this study and other experimental
data with direct and indirect nitric oxide donors, the crucial
point especially in failing hearts with impaired diastolic and
systolic function lies in nitric oxide bioavailability during I/
R. By enhancement of nitric oxide bioavailability, two major
problems of hypertrophied, remodeled hearts can be attenu-1010 The Journal of Thoracic and Cardiovascular Sated: diastolic dysfunction, indicated by reduced diastolic re-
laxation, leading to systolic dysfunction, and enhanced
metabolic demand caused by myocardial hypertrophy.
Therefore, ERA provides an interesting pharmacologic pro-
file by (1) counteracting the detrimental effects of ET-1 in I/
R and heart failure and by (2) enhancing nitric oxide bio-
availability. Consequently, acute ERA as an adjunct to cur-
rent cardioplegic techniques may provide an additional
benefit in patients with poor ejection fraction by preserving
endothelial function and improving myocardial protection.
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C
P
SFIGUREE1. Ex vivo hemodynamic measurements in absolute values. A: Coronary flow (CF). ERA acute versus both ERA chronic and control groups;*P<
.01. B, Cardiac output (left atrial flow, LAF). ERA acute versus control group, yP<.05; ERA chronic versus control group, #P<.01. C, External heart work
(EHW) (cardiac output3 LV systolic pressure). ERA acute versus control group, *P<.01; ERA chronic versus control group; #P<.01. D, Diastolic left atrial
pressure (LAP dia). *P< .01 ERA acute versus control group. All data are presented as mean  SEM. BL, Baseline.
TABLE E1. With sham-operated group
Control (n ¼ 12) ERA chronic (n ¼ 15) ERA acute (n ¼ 12) Sham-operated (n ¼ 8)
Part I: Echocardiographic data
LVEDD (cm) 1.14  0.05 1.01  0.01* 1.2  0.04 0.92  0.04y
LVESD (cm) 1.01  0.06 0.82  0.01* 1.05  0.02 0.63  0.04y
EF 0.28  0.04 0.82  0.01* 1.05  0.02 0.63  0.04y
Part II: Baseline working heart data
CF (mL $ min1 $ g1 HW) 2.72  0.35 2.71  0.48 2.89  0.51 4.2  0.59y
CO (mL $ min1 $ g1 HW) 20.06  3.68 32.94  2.86* 22.98  4.62 58.46  14.26y
EHW (g 3 m $ min1 $ g1) 3365  427 5963  737* 3862  613 7098  483y
*P< .05 vs both control and ERA acute. yP< .05 vs control, ERA acute, and ERA chronic.
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